VERTEX PHARMACEUTICALS INC / MA
VRTXNasdaq · SIC 2834
$485.65
↓ -0.1%Jul 17 close · end-of-day
Price
1Y↑ +3.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$124.5B
Enterprise Value
$117.2B
P/E
28.8
P/S
10.2
P/B
6.4
EV/EBITDA
23.9
PEG
4.7
FCF Yield
3.0%
Dividend Yield
—
Revenue (TTM)
$12.2B
Net Income (TTM)
$4.3B
Free Cash Flow (TTM)
$3.7B
Gross Margin
—
Operating Margin
38.3%
Net Margin
35.5%
ROE
22.4%
ROIC
32.5%
Debt / Equity
—
Net Cash
$7.2B
Return 1Y
+4.8%
Company profile
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial.
- CEO
- Reshma Kewalramani
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 4,800
- Headquarters
- Massachusetts
- Website
- vrtx.com
Management & directors
- Mckechnie DuncanEVP, Chief Commercial Officer
- Tatsis OuraniaEVP, Chief Reg. & Quality Off.
- Liu JoyEVP and Chief Legal Officer
- Bozic CarmenEVP and CMO
- Bunnage Mark E.EVP, Chief Scientific Officer
- Ambrose KristenSVP & Chief Accounting Officer
- Atkinson Edward Morrow IiiEVP, Chief Technical Ops. Off.
- Biller JonathanEVP and Chief Legal Officer
- Sachdev AmitEVP Chief Patient & Ext Af Off
- Kewalramani ReshmaCEO & President
- Leiden Jeffrey MExecutive Chairman
- Wagner Charles F JrEVP, CO & FO
Roles derived from SEC Form 4 filings.
Earnings
Next earnings · estimated2026-08-03
VRTX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$3.0B↑ +7.8%
Diluted EPS$4.02↑ +61.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $6.2B | $7.6B | $8.9B | $9.9B | $11.0B | $12.0B |
| Gross profit | — | — | — | — | — | — |
| Operating income | $2.9B | $2.8B | $4.3B | $3.8B | -$232.9M | $4.2B |
| Net income | $2.7B | $2.3B | $3.3B | $3.6B | -$535.6M | $4.0B |
| Diluted EPS | $10.29 | $9.01 | $12.82 | $13.89 | -$2.08 | $15.32 |
| Operating cash flow | $3.3B | $2.6B | $4.1B | $3.5B | -$492.6M | $3.6B |
| Free cash flow | $3.0B | $2.4B | $3.9B | $3.3B | -$790.3M | $3.2B |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 46.0% | 36.7% | 48.2% | 38.8% | -2.1% | 34.8% |
| Net margin | 43.7% | 30.9% | 37.2% | 36.7% | -4.9% | 32.9% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.6B | $2.8B | $2.9B | $2.8B | $3.0B | $3.1B | $3.2B | $3.0B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$3.5B | $1.1B | $1.0B | $630.1M | $1.2B | $1.2B | $1.2B | $1.1B |
| Net income | -$3.6B | $1.0B | $913.0M | $646.3M | $1.0B | $1.1B | $1.2B | $1.0B |
| Diluted EPS | -$13.92 | $4.01 | $3.62 | $2.49 | $3.99 | $4.20 | $4.64 | $4.02 |
| Operating cash flow | -$3.8B | $1.4B | $584.6M | $818.9M | $1.1B | $1.2B | $498.0M | $1.4B |
| Free cash flow | -$3.8B | $1.3B | $492.0M | $778.2M | $927.4M | $1.1B | $348.6M | $1.3B |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -132.9% | 40.3% | 35.2% | 22.7% | 38.8% | 38.6% | 37.8% | 38.1% |
| Net margin | -135.8% | 37.7% | 31.4% | 23.3% | 34.8% | 35.2% | 37.3% | 34.5% |
Company news
Jul 20, 2026
- 11h agoHow FDA’s Pediatric Expansion of Casgevy at Vertex Pharmaceuticals (VRTX) Has Changed Its Investment Storyfinance.yahoo.com
- 16h agoVertex Pharmaceuticals (VRTX) Wins FDA Nod To Treat Children As Young As 2finance.yahoo.com
- 21h agoVertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watchingfool.com
Jul 16, 2026
- 4d ago1 Nasdaq 100 Stock to Keep an Eye On and 2 We Questionfinance.yahoo.com
- 4d agoCollect 9.8% On VRTX Stock Now, And Still Keep 15% Of Upsidetrefis.com
- 4d agoVertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on Itfinance.yahoo.com
- 4d agoVortex Energy Provides Corporate Update on Robinsons River Salt Project Technical Studyfinance.yahoo.com
Jul 15, 2026
Jul 14, 2026
Jul 13, 2026
- 6d agoVertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investorsfinance.yahoo.com
- 6d agoVortex Energy Corp. Announces Closing of LIFE Offeringfinance.yahoo.com
- 7d agoDoes Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?fool.com
- 7d agoWhat to Expect From Vertex Pharmaceuticals' Next Quarterly Earnings Reportbarchart.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-02 | McKechnie Duncan· EVP, Chief Commercial Officer | Sale | 1,541 | $519.00 | $799,779.00 | filing |
| 2026-07-02 | Tatsis Ourania· EVP, Chief Reg. & Quality Off. | Sale | 1,500 | $524.99 | $787,485.00 | filing |
| 2026-07-01 | Liu Joy· EVP and Chief Legal Officer | Sale | 828 | $502.71 | $416,243.88 | filing |
| 2026-06-26 | Bozic Carmen· EVP and CMO | Sale | 596 | $482.50 | $287,570.00 | filing |
| 2026-06-18 | Bozic Carmen· EVP and CMO | Sale | 1,020 | $462.17 | $471,413.40 | filing |
| 2026-06-15 | Bozic Carmen· EVP and CMO | Sale | 4,062 | $450.00 | $1.8M | filing |
| 2026-06-05 | Bozic Carmen· EVP and CMO | Sale | 1,745 | $450.00 | $785,250.00 | filing |
| 2026-06-01 | Liu Joy· EVP and Chief Legal Officer | Sale | 828 | $439.91 | $364,245.48 | filing |
| 2026-05-29 | Bozic Carmen· EVP and CMO | Sale | 1,974 | $450.00 | $888,300.00 | filing |
| 2026-05-15 | Bozic Carmen· EVP and CMO | Sale | 1,354 | $453.45 | $613,971.30 | filing |
| 2026-05-15 | Bunnage Mark E.· EVP, Chief Scientific Officer | Sale | 33 | $453.45 | $14,963.85 | filing |
| 2026-05-12 | Bozic Carmen· EVP and CMO | Sale | 6,988 | $450.00 | $3.1M | filing |
| 2026-05-04 | Bhatia Sangeeta N. | Sale | 318 | $423.73 | $134,746.14 | filing |
| 2026-05-01 | Liu Joy· EVP and Chief Legal Officer | Sale | 1,104 | $425.02 | $469,222.08 | filing |
| 2026-05-01 | Bhatia Sangeeta N. | Award | 943 | $0.00 | $0.00 | filing |
| 2026-05-01 | Thornberry Nancy | Award | 472 | $0.00 | $0.00 | filing |
| 2026-05-01 | Garber Alan M | Award | 472 | $0.00 | $0.00 | filing |
| 2026-05-01 | Schneider Jennifer | Award | 472 | $0.00 | $0.00 | filing |
| 2026-05-01 | MCKENZIE DIANA | Award | 943 | $0.00 | $0.00 | filing |
| 2026-05-01 | MCKENZIE DIANA | D | 796 | — | — | filing |
| 2026-05-01 | Upadhyay Suketu | D | 796 | — | — | filing |
| 2026-05-01 | Thornberry Nancy | D | 398 | — | — | filing |
| 2026-05-01 | Schneider Jennifer | D | 796 | — | — | filing |
| 2026-04-01 | Liu Joy· EVP and Chief Legal Officer | Sale | 978 | $449.17 | $439,288.26 | filing |
| 2026-03-27 | Bozic Carmen· EVP and CMO | Sale | 2,329 | $450.95 | $1.1M | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.